PPARδ agonist is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-03-02. Numbers and descriptions here follow the published literature rather than marketing material.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Laird announced that the first U.S. forces to leave South Vietnam would be 900 infantrymen from the 9th Infantry Division. Prime Minister of Laos Souvanna Phouma acknowledged that U.S. aircraft regularly carried out bombing missions over Laos.
== Laboratory performance == Newborn screening programs participate in quality control programs as in any other laboratory, with some notable exceptions. Much of the success of newborn screening programs is dependent on the filter paper used for the collection of the samples. Initial studies using Robert Guthrie's test for PKU reported high false positive rates that were attributed to a poorly selected type of filter paper. This source of variation has been eliminated in most newborn screening programs through standardization of approved sources of filter paper for use in newborn screening programs. In most regions, the newborn screening card (which contains demographic information as well as attached filter paper for blood collection) is supplied by the organization carrying out the testing, to remove variations from this source.
== Medical uses == Cetacaine is a benzocaine-based anesthetic that also contains other active ingredients that include butamben and tetracaine hydrochloride. The main use for this drug is to produce anesthesia to mucous membranes to numb and help control the pain in that area. The spray form of Cetacaine is also used to help prevent gagging in the patient. The anesthetic effect of Cetacaine can be expected to take effect in about 30 seconds and last between 30–60 minutes depending on location and application amount. Cetacaine can and has been used for surgeries that include bronchi, ear, esophagus, larynx, mouth, nose, pharynx, rectal, and vaginal procedures. These procedures can include periodontal treatment, pre-probing, pre-scaling/root planning procedures, pre-injection, and laser dentistry.
The four main components of extremities are bones, vessels, nerves, and soft tissues. Gunshot wounds can thus cause severe bleeding, fractures, nerve deficits, and soft tissue damage. The Mangled Extremity Severity Score (MESS) is used to classify the severity of injury and evaluates for severity of skeletal and/or soft tissue injury, limb ischemia, shock, and age. Depending on the extent of injury, management can range from superficial wound care to limb amputation. Vital sign stability and vascular assessment are the most important determinants of management in extremity injuries. As with other traumatic cases, those with uncontrolled bleeding require immediate surgical intervention. If surgical intervention is not readily available and direct pressure is insufficient to control bleeding, tourniquets or direct clamping of visible vessels may be used temporarily to slow active bleeding. People with hard signs of vascular injury also require immediate surgical intervention. Hard signs include active bleeding, expanding or pulsatile hematoma, bruit/thrill, absent distal pulses and signs of extremity ischemia. For stable people without hard signs of vascular injury, an injured extremity index (IEI) should be calculated by comparing the blood pressure in the injured limb compared to an uninjured limb in order to further evaluate for potential vascular injury. If the IEI or clinical signs are suggestive of vascular injury, the person may undergo surgery or receive further imaging including CT angiography or conventional arteriography.
We knew the world would not be the same. A few people laughed, a few people cried, and most people were silent. I remembered the line from the Hindu scripture the Bhagavad Gita. Vishnu is trying to persuade the prince that he should do his duty and to impress him takes on his multiarmed form and says, "Now, I am become Death, the destroyer of worlds." I suppose we all thought that one way or another.
Sources: en.wikipedia.org
The industrial potential of fermentation was outgrowing its traditional home in brewing, and "zymotechnology" soon gave way to "biotechnology." With food shortages spreading and resources fading, some dreamed of a new industrial solution. The Hungarian Károly Ereky coined the word "biotechnology" in Hungary during 1919 to describe a technology based on converting raw materials into a more useful product. He built a slaughterhouse for a thousand pigs and also a fattening farm with space for 50,000 pigs, raising over 100,000 pigs a year. The enterprise was enormous, becoming one of the largest and most profitable meat and fat operations in the world. In a book entitled Biotechnologie, Ereky further developed a theme that would be reiterated through the 20th century: biotechnology could provide solutions to societal crises, such as food and energy shortages. For Ereky, the term "biotechnologie" indicated the process by which raw materials could be biologically upgraded into socially useful products. This catchword spread quickly after the First World War, as "biotechnology" entered German dictionaries and was taken up abroad by business-hungry private consultancies as far away as the United States. In Chicago, for example, the coming of prohibition at the end of World War I encouraged biological industries to create opportunities for new fermentation products, in particular a market for nonalcoholic drinks.
A third, only marginally related concept was proposed in 1923 by Gilbert N. Lewis, which includes reactions with acid–base characteristics that do not involve a proton transfer. A Lewis acid is a species that accepts a pair of electrons from another species; in other words, it is an electron pair acceptor. Brønsted acid–base reactions are proton transfer reactions while Lewis acid–base reactions are electron pair transfers. Many Lewis acids are not Brønsted–Lowry acids. Contrast how the following reactions are described in terms of acid–base chemistry:
=== Purification methods === Recovering uranium and plutonium from spent nuclear fuel for reuse is one of the major processes of the nuclear fuel cycle. As it has a long half-life of just over 2 million years, the alpha emitter 237Np is one of the major isotopes of the minor actinides separated from spent nuclear fuel. Many separation methods have been used to separate out the neptunium, operating on small and large scales. The small-scale purification operations have the goals of preparing pure neptunium as a precursor of metallic neptunium and its compounds, and also to isolate and preconcentrate neptunium in samples for analysis. Most methods that separate neptunium ions exploit the differing chemical behaviour of the differing oxidation states of neptunium (from +3 to +6 or sometimes even +7) in solution. Among the methods that are or have been used are: solvent extraction (using various extractants, usually multidentate β-diketone derivatives, organophosphorus compounds, and amine compounds), chromatography using various ion-exchange or chelating resins, coprecipitation (possible matrices include LaF3, BiPO4, BaSO4, Fe(OH)3, and MnO2), electrodeposition, and biotechnological methods. Currently, commercial reprocessing plants use the Purex process, involving the solvent extraction of uranium and plutonium with tributyl phosphate.
== Research == A relatively recent avenue of drug research in treating depression and drug addiction is through PPARα and PPARγ activation. Both TLR4-mediated and NF-κB-mediated signalling pathways have been implicated in the development of addiction to several drugs such as opioids and cocaine, and therefore are appealing targets for pharmacotherapy. Despite a breadth of preclinical research showing potential in animal models in the treatment of drug addictions including alcohol, nicotine, cocaine, opioids and methamphetamine, the human evidence is limited with the amount of trials looking at using PPAR agonists for humans still being low; and so far (as of 2020) not being particularly promising. There are several suggested hypotheses for the poor translation from animal to human research evidence such as the potency and selectivity of PPAR ligands, sex-related variability, and species differences in the distribution and signaling of PPAR.
=== Aftermath of the conflict === According to the cable sent from Astana, Chinese Ambassador Cheng Guoping told American Ambassador to Kazakhstan in June 2009 that he expected Russia to use military force to depose Saakashvili. US Ambassador to Russia John Beyrle advised the US government in June 2009 against military cooperation with Georgia since it would harm "re-start relations with Russia", while US Ambassador to Georgia supported maintaining ties with Georgia. The cables reported that Assistant Secretary of State Philip H. Gordon was told by the French diplomatic adviser Jean-David Levitte in September 2009 that "it may take a generation before the Russian public will be able to accept their loss of influence, from Poland and the Baltics to Ukraine and Georgia. Unfortunately, the Russian tendency is to view « good neighbors » as totally submissive subordinates." Gordon said that "the U.S. pursues a policy to support Georgia in the face of Russian pressure without encouraging President Saakashvili to act in ways that are unhelpful." In September 2009, United States Assistant Secretary of Defense Alexander Vershbow told Russian Deputy Foreign Minister Grigory Karasin that the US non-lethal military aid to Georgia was "a matter of principle" and the US did "not accept any arms embargo".
Sources: en.wikipedia.org
Since the 1999 publication of Good Manufacturing Practice for Active Pharmaceutical Ingredients, by the International Conference on Harmonization (ICH), GMPs now apply in those countries and trade groupings that are signatories to ICH (the EU, Japan and the U.S.), and applies in other countries (e.g., Australia, Canada, Singapore) which adopt ICH guidelines for the manufacture and testing of active raw materials.
LeuT, which is also a member of the NSS family that functions as an amino acid transporter, was crystallized from Aquifex aeolicus by Yamashita et al., and shares 20-25% identity in primary structure with the human neurotransmitter transporters. Therefore, the crystal structure of LeuT and its transport mechanism have been proven to be a good model system for the study of NSS proteins. Although detailed transport mechanism of the NSS proteins is not fully understood, it is clear that in order for transport to occur a rearrangement of large proteins needs to take place. LeuT has been co-crystallised with sertraline and (R)- and (S)-fluoxetine where the SSRIs have been found to bind as non-competitive inhibitors in a vestibule binding site (can be looked at as a second binding site), which is separated from the drugs binding site by the site chains of the two aromatic amino acids of the extracellular gate of the transport protein. The halogens on the SSRIs chemical structure all bind to the same HBP within LeuT and interact with similar amino acids, but the amino acid sequence in the HBP is highly preserved between LeuT and SERT. That suggest that in the human SERT the SSRIs also bind both at the same position and with similar manner, which is a key feature making the SSRIs selective for SERT. Conversely, there could be differences in their binding where the other part of the drug molecule will likely bind to SERT in a different way, given the diversity in their structure.
=== Antiestrogenic effects === Progesterone, like all progestogens, has antiestrogenic effects in certain tissues such as the uterus, cervix, vagina, and breasts, and possibly also the brain. These effects are mediated by activation of the PR in these tissues. Progesterone does not have antiestrogenic effects in the more conventional sense of binding to and antagonizing the ER or binding to and inhibiting enzymes involved in estrogen biosynthesis. Instead, for instance in the endometrium, progesterone causes downregulation of the ER and upregulation of the estrogen-inactivating enzymes 17β-hydroxysteroid dehydrogenase 2 (converts estradiol into estrone) and estrone sulfotransferase (converts estrone into estrone sulfate). The antiestrogenic effects of progesterone and other progestogens form the basis for their only approved indication in menopausal hormone therapy: prevention of long-term unopposed estrogen-induced endometrial hyperplasia and increased endometrial cancer risk in women with intact uteruses. In the breasts, progesterone and other progestogens downregulate the ER as well as the estrogen-activating enzymes steroid sulfatase (converts estrone sulfate into estrone) and 17β-hydroxysteroid-dehydrogenase 1 (converts estrone into estradiol) and upregulates estrone sulfotransferase. However, other studies suggest that progestogens do not downregulate ER expression in the breasts. When applied directly to the breasts in women, progesterone can block the proliferative effects of estradiol.
Arsenic trioxideα Asparaginaseα Bendamustineα Bleomycinα Calcium folinate (leucovorin calcium)α Capecitabineα Carboplatinα Chlorambucilα Cisplatinα Cyclophosphamideα Cytarabineα Dacarbazineα Dactinomycinα Daunorubicinα Docetaxelα Doxorubicinα Doxorubicin (as pegylated liposomal)α Etoposideα Fludarabineα Fluorouracilα Gemcitabineα Hydroxycarbamide (hydroxyurea)α Ifosfamideα Irinotecanα Melphalanα Mercaptopurineα Methotrexateα Oxaliplatinα Paclitaxelα Pegaspargaseα Procarbazineα Realgar Indigo naturalis formulationα Tioguanineα Vinblastineα Vincristineα Vinorelbineα
Hydrophilic interaction chromatography (or hydrophilic interaction liquid chromatography, HILIC) is a type of liquid chromatography that uses a hydrophilic stationary phase and a high-organic mobile phase for the separation of analytes by polarity. While it is not as popular as some other types of liquid chromatography, the number of scientific publications using HILIC have greatly increased since the early 2000s. HILIC is similar to reverse phase chromatography in its mobile phase composition, and also to normal phase chromatography, with its polar stationary phase. It also has overlap with ion exchange chromatography. Sometimes, HILIC is considered to be a hybrid of these techniques. HILIC was named in 1990 by Andrew Alpert, who described it as a type of liquid-liquid partition chromatography. He suggested that analytes elute in order of increasing polarity, a conclusion supported by review and re-evaluation of published data. The mechanism for HILIC is still not entirely understood, but it is thought to rely on analytes partitioning between the organic-rich mobile phase and a water-enriched layer that forms of the surface of the polar stationary phase, in a liquid-liquid extraction system. More polar analytes will have stronger interactions with the water-enriched layer and with the column itself, therefore being retained on the column for longer.
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
Cardarine targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not bind the androgen receptor in the way SARMs do.